false000172312800017231282025-05-082025-05-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 8, 2025
AMNEAL PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware001-3848593-4225266
(State or other jurisdiction
of incorporation)		(Commission File Number)(IRS Employer
Identification No.)
400 Crossing Blvd
Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (908) 947-3120
N/A
(Former Name or Former Address, if Changed Since Last Report) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: 
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A Common Stock, par value $0.01 per shareAMRXThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.07
Submission of Matters to a Vote of Security Holders.

Amneal Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) on May 6, 2025. Each of the proposals was approved, and each of the director nominees was elected, by the vote of the stockholders at the Annual Meeting as follows:
Proposal 1: To elect the following director nominees to hold office until the 2025 Annual Meeting of Stockholders and until their respective successors are elected and qualified:
 
 
For
 
 
Against
 
 
Abstain
 
 
Broker Non-Votes
 
Emily Peterson Alva
 
 
258,746,677
1,549,356
25,468
29,134,445
 
Deb Autor
 
 
258,775,698



1,519,874


25,929



29,134,445
 
J. Kevin Buchi


257,353,899



2,740,560


227,042



29,134,445

Jeff George
 
 
258,597,328



1,697,135


27,038



29,134,445
 
John Kiely
 
 
257,525,966



2,568,488


227,047



29,134,445
 
Paul Meister
 
 
239,786,615


20,307,492


227,394



29,134,445
 
Ted Nark
 
 
257,861,624



2,225,579


234,298



29,134,445
 
Chintu Patel
 
 
259,451,886



840,909


28,706



29,134,445
 
Chirag Patel
 
 
259,263,024



1,029,755


28,722



29,134,445
 
Gautam Patel
 
 
256,035,302



4,257,416


28,783



29,134,445

Shlomo Yanai
 
 
258,502,824



1,791,220


27,457



29,134,445
 

Proposal 2: To approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers:
For
 
Against
 
Abstain
 
Broker Non-Votes
258,800,579
1,255,182
265,740
29,134,445

Proposal 3:Advisory vote to approve the Frequency of Future “Say on Pay” votes:
1 Year
 2 Years
3 Years
 
Abstain
 
Broker Non-Votes
255,051,542
53,168
5,178,739
38,052

0


Proposal 4: To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025:
For
 
Against
 
Abstain
 
Broker Non-Votes
288,989,309

452,503
14,134

0







SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 8, 2025AMNEAL PHARMACEUTICALS, INC.
By:/s/ Jason B. Daly
Name:Jason B. Daly
Title:Executive Vice President, Chief Legal Officer and Corporate Secretary